NEO
NeoGenomics Inc
18.50$
+3.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 100.0% | 96.5% | 13.7% | 20.1% | 33.2% | 63.0% | 60.5% | 63.7% | 59.7% | 65.8% | 64.0% | 66.1% | 61.8% | 68.9% | 72.4% | 26.9% | 23.4% | 24.7% | 20.5% | 41.0% | 45.4% | 36.4% | 34.8% | 35.5% | 36.4% | 27.7% | |
| 100.0% | 94.9% | – | 4.9% | 19.0% | 1.0% | 4.0% | 3.2% | 6.4% | 12.6% | 8.0% | 13.2% | 6.2% | 12.1% | 41.5% | 6.4% | 3.7% | 3.7% | 1.9% | 24.4% | 23.1% | 16.9% | 15.1% | 20.4% | 22.4% | 11.7% | |
| 100.0% | 94.9% | – | 4.9% | 19.0% | 1.0% | 4.0% | 3.2% | 6.4% | 12.6% | 8.0% | 13.2% | 6.2% | 12.1% | 41.5% | 6.4% | 3.7% | 3.7% | 1.9% | 24.4% | 30.0% | 27.6% | 25.2% | 24.7% | 23.6% | 11.7% | |
| – | – | 9.0% | 12.6% | 9.5% | 51.0% | 49.5% | 49.6% | 39.9% | 35.8% | 38.4% | 39.6% | 46.7% | 46.7% | 25.2% | 13.3% | 16.5% | 17.6% | 15.2% | 13.4% | 10.8% | 6.0% | 6.9% | 7.8% | 9.2% | 11.7% | |
| – | – | 4.3% | 2.1% | 2.6% | 5.6% | 3.7% | 4.7% | 6.7% | 4.6% | 6.5% | 6.0% | 6.2% | 5.8% | 3.2% | 1.4% | 1.9% | 2.2% | 1.7% | 2.0% | 3.0% | 1.3% | 1.4% | 1.4% | 1.6% | 2.1% | |
| – | 3.7% | 85.5% | 78.5% | 66.4% | 35.4% | 38.4% | 32.3% | 39.4% | 33.5% | 35.4% | 33.3% | 28.6% | 24.3% | 18.6% | 9.4% | 10.1% | 10.6% | 12.1% | 9.0% | 8.7% | 11.3% | 5.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 0.0% | 9.3% | 6.5% | 3.6% | 39.8% | 43.6% | 42.8% | 39.2% | 28.0% | 21.4% | 28.2% | 30.0% | 31.1% | 31.9% | 38.6% | |
| – | – | – | – | – | – | – | – | – | – | – | 0.0% | 9.3% | 6.5% | 5.2% | 23.9% | 22.9% | 21.6% | 27.7% | 17.8% | 12.2% | 23.7% | 23.5% | 22.2% | 20.7% | 21.1% | |
| 67,219.9% | 228.9% | 94.8% | 172.5% | 172.1% | 192.1% | 98.3% | 64.4% | 79.4% | 56.4% | 77.0% | 70.4% | 69.4% | 45.6% | 25.5% | 35.3% | 44.6% | 40.1% | 36.5% | 28.5% | 29.8% | 40.7% | 42.6% | 44.0% | 44.9% | 38.5% | |
| 67,219.9% | 228.9% | 94.8% | 56.2% | 172.1% | 61.6% | 83.9% | 51.6% | 60.2% | 44.6% | 67.2% | 57.4% | 59.1% | 35.9% | 18.0% | 10.9% | 17.8% | 10.2% | 12.1% | 9.0% | 7.4% | 4.7% | 5.2% | 5.7% | 18.4% | 6.5% | |
| – | – | 3.0% | 9.0% | 12.2% | – | 55.2% | 3.7% | 24.5% | 15.7% | 39.8% | 30.1% | 35.5% | 17.7% | 4.0% | 3.8% | 9.1% | 2.6% | 4.1% | 1.9% | 0.8% | 0.5% | 0.4% | 0.3% | 12.5% | 0.4% | |
| 5,623.7% | 23.7% | 26.8% | 13.9% | 16.3% | 42.9% | 22.3% | 27.6% | 20.7% | 15.2% | 14.2% | 12.7% | 12.0% | 10.5% | 7.8% | 3.4% | 8.7% | 3.0% | 3.5% | 2.8% | 2.5% | 1.0% | 1.2% | 1.2% | 1.3% | 1.7% | |
| – | – | – | 116.4% | – | – | 14.3% | 12.8% | 19.2% | 11.8% | 9.9% | 13.1% | 10.3% | 8.3% | 6.5% | 14.2% | 27.3% | 26.5% | 18.4% | 12.9% | 17.0% | 28.5% | 30.8% | 32.0% | 20.8% | 25.1% | |
| -67,119.9% | -128.9% | 5.2% | -72.5% | -72.1% | -92.1% | 1.7% | 35.6% | 20.6% | 43.6% | 23.0% | 29.6% | 30.6% | 54.4% | 74.5% | 64.7% | 55.4% | 59.9% | 63.5% | 71.5% | 70.2% | 59.3% | 57.4% | 56.0% | 55.1% | 61.5% | |
| -777,863.4% | -9,930.7% | -1,935.6% | -1,709.6% | -1,693.1% | -1,020.3% | -356.0% | -222.8% | -218.1% | -140.2% | -157.2% | -113.5% | -75.1% | -51.5% | -23.9% | -6.0% | -15.6% | -16.7% | -10.1% | -1.6% | -0.7% | -0.8% | -9.1% | -14.7% | -19.9% | -31.9% | |
| 84,083.9% | 927.2% | 191.5% | 567.4% | 702.2% | 417.1% | 167.1% | 96.2% | 86.4% | 53.5% | 54.7% | 42.9% | 32.4% | 26.4% | 13.8% | 3.3% | 23.0% | 4.6% | 3.6% | 2.9% | 2.3% | 1.3% | 1.4% | 1.5% | 1.5% | 1.9% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.